Drug Profile

Research programme: anti-VISTA antibodies - ImmuNext

Latest Information Update: 21 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmuNext
Developer Curis; ImmuNext
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Jan 2024 Option and license agreement between Curis and ImmuNext expires for VISTA antagonizing compounds, including CI 8993 in January 2024
30 Dec 2022 No development reported - Preclinical for Cancer in USA (Parenteral)
07 Jan 2020 Early research for Cancer is ongoing in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com